COgnitive-pulmonary disease

Fiona A H M Cleutjens, Daisy J A Janssen, Rudolf W H M Ponds, Jeanette B Dijkstra, Emiel F M Wouters, Fiona A H M Cleutjens, Daisy J A Janssen, Rudolf W H M Ponds, Jeanette B Dijkstra, Emiel F M Wouters

Abstract

Over the past few decades, chronic obstructive lung disease (COPD) has been considered a disease of the lungs, often caused by smoking. Nowadays, COPD is regarded as a systemic disease. Both physical effects and effects on brains, including impaired psychological and cognitive functioning, have been demonstrated. Patients with COPD may have cognitive impairment, either globally or in single cognitive domains, such as information processing, attention and concentration, memory, executive functioning, and self-control. Possible causes are hypoxemia, hypercapnia, exacerbations, and decreased physical activity. Cognitive impairment in these patients may be related to structural brain abnormalities, such as gray-matter pathologic changes and the loss of white matter integrity which can be induced by smoking. Cognitive impairment can have a negative impact on health and daily life and may be associated with widespread consequences for disease management programs. It is important to assess cognitive functioning in patients with COPD in order to optimize patient-oriented treatment and to reduce personal discomfort, hospital admissions, and mortality. This paper will summarize the current knowledge about cognitive impairment as extrapulmonary feature of COPD. Hereby, the impact of smoking on cognitive functioning and the impact of cognitive impairment on smoking behaviour will be examined.

Figures

Figure 1
Figure 1
Cognitive domains and specific functions.
Figure 2
Figure 2
Nicotinic stimulation results are a reflection of baseline cognitive performance level (data from Figure  1 in [25]).

References

    1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine. 2006;3(11):2011–2030.
    1. Kenfield SA, Stampfer MJ, Rosner BA, Colditz GA. Smoking and smoking cessation in relation to mortality in women. Journal of the American Medical Association. 2008;299(17):2037–2047.
    1. Eisner MD, Balmes J, Katz PP, Trupin L, Yelin EH, Blanc PD. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. Environmental Health: A Global Access Science Source. 2005;4:p. 7.
    1. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American Journal of Respiratory and Critical Care Medicine. 2013;187:347–365.
    1. Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. European Respiratory Journal. 2010;35(4):913–922.
    1. Baltes PB, et al. Life-span theory in developmental psychology. In: Lerner RM, editor. Handbook of Child Psychology. Theoretical Models of Human Development. 6th edition. Vol. 1. New York, NY, USA: Wiley; 2006. pp. 569–664.
    1. Cummings JL, Miller BL. Conceptual and Clinical Aspects of the Frontal Lobes. The Human Frontal Lobes: Functions and Disorders. New York, NY, USA: Guilford; 2007.
    1. Hofmann W, Schmeichel BJ, Baddeley AD. Executive functions and self-regulation. Trends in Cognitive Sciences. 2012;16:174–180.
    1. Grant I, Heaton RK, McSweeney AJ. Neuropsychologic findings in hypoxemic chronic obstructive pulmonary disease. Archives of Internal Medicine. 1982;142(8):1470–1476.
    1. Hynninen KMJ, Breitve MH, Wiborg AB, Pallesen S, Nordhus IH. Psychological characteristics of patients with chronic obstructive pulmonary disease: a review. Journal of Psychosomatic Research. 2005;59(6):429–443.
    1. Stuss DT, Peterkin I, Guzman DA, Guzman C, Troyer AK. Chronic obstructive pulmonary disease: effects of hypoxia on neurological and neuropsychological measures. Journal of Clinical and Experimental Neuropsychology. 1997;19(4):515–524.
    1. Dodd JW, Charlton RA, van den Broek MD, Jones PW. Cognitive dysfunction in patients hospitalized with acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Chest. 2013;144(1):119–127.
    1. Incalzi RA, Gemma A, Marra C, Muzzolon R, Capparella O, Carbonin P. Chronic obstructive pulmonary disease: An original model of cognitive decline. American Review of Respiratory Disease. 1993;148(2):418–424.
    1. Thakur N, Blanc PD, Julian LJ, et al. COPD and cognitive impairment: the role of hypoxemia and oxygen therapy. International Journal of Chronic Obstructive Pulmonary Disease. 2010;5:263–269.
    1. Hung WW, Wisnivesky JP, Siu AL, Ross JS. Cognitive decline among patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2009;180:134–137.
    1. Lezak M. Neuropsychological Assessment. 4th edition. New York, NY, USA: Oxford University Press; 2004.
    1. Janssen DJA, Spruit MA, Uszko-Lencer NH, Schols JMGA, Wouters EFM. Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure. Journal of Palliative Medicine. 2011;14(6):735–743.
    1. Zhang H, Wang X, Lin J, et al. Grey and white matter abnormalities in chronic obstructive pulmonary disease: a case-control study. BMJ Open. 2012;2e000844
    1. Ryu CW, Jahng G-H, Choi CW, et al. Microstructural change of the brain in chronic obstructive pulmonary disease: a voxel-based investigation by MRI. Chronic Obstructive Pulmonary Disease. 2013;10:357–366.
    1. Ortapamuk H, Naldoken S. Brain perfusion abnormalities in chronic obstructive pulmonary disease: comparison with cognitive impairment. Annals of Nuclear Medicine. 2006;20(2):99–106.
    1. Mansvelder HD, Van Aerde KI, Couey JJ, Brussaard AB. Nicotinic modulation of neuronal networks: from receptors to cognition. Psychopharmacology. 2006;184(3-4):292–305.
    1. Le Houezec J. Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review. International Journal of Tuberculosis and Lung Disease. 2003;7(9):811–819.
    1. Ashton H, Millman JE, Telford R, Thompson JW. Stimulant and depressant effects of cigarette smoking on brain activity in man. British Journal of Pharmacology. 1973;48(4):715–717.
    1. Jiloha RC. Biological basis of tobacco addiction: implications for smoking-cessation treatment. Indian Journal of Psychiatry. 2010;52(4):301–307.
    1. Newhouse PA, Potter A, Singh A. Effects of nicotinic stimulation on cognitive performance. Current Opinion in Pharmacology. 2004;4:36–46.
    1. Jasinska AJ, Zorick T, Brody AL, Stein EA. Dual role of nicotine in addiction and cognition: a review of neuroimaging studies in humans. Neuropharmacology. 2013
    1. Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology. 2010;210(4):453–469.
    1. Hill RD, Nilsson L-G, Nyberg L, Bäckman L. Cigarette smoking and cognitive performance in healthy Swedish adults. Age and Ageing. 2003;32(5):548–550.
    1. Durazzo TC, Meyerhoff DJ, Nixon SJ. Chronic cigarette smoking: implications for neurocognition and brain neurobiology. International Journal of Environmental Research and Public Health. 2010;7(10):3760–3790.
    1. Caspers K, Arndt S, Yucuis R, McKirgan L, Spinks R. Effects of alcohol- and cigarette-use disorders on global and specifi c measures of cognition in middle-age adults. Journal of Studies on Alcohol and Drugs. 2010;71(2):192–200.
    1. Jacobsen LK, Krystal JH, Mencl WE, Westerveld M, Frost SJ, Pugh KR. Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. Biological Psychiatry. 2005;57(1):56–66.
    1. Dwyer JB, Broide RS, Leslie FM. Nicotine and brain development. Birth Defects Research C: Embryo Today: Reviews. 2008;84(1):30–44.
    1. Ott A, Andersen K, Dewey ME, et al. Effect of smoking on global cognitive function in nondemented elderly. Neurology. 2004;62(6):920–924.
    1. Sabia S, Marmot M, Dufouil C, Singh-Manoux A. Smoking history and cognitive function in middle age from the Whitehall II study. Archives of Internal Medicine. 2008;168(11):1165–1173.
    1. Rusanen M, Kivipelto M, Quesenberry CP, Jr., Zhou J, Whitmer RA. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Archives of Internal Medicine. 2011;171(4):333–339.
    1. Emery CF, Huppert FA, Schein RL. Do pulmonary function and smoking behavior predict cognitive function? Findings from a british sample. Psychology and Health. 1997;12(2):265–275.
    1. Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. European Respiratory Journal. 2010;35:913–922.
    1. Ahrens D, Bandi P, Ullsvik J, Moberg DP. Who smokes? A demographic analysis of Wisconsin smokers. Wisconsin Medical Journal. 2005;104(4):18–22.
    1. Smith SS, Beckley T, Fiore MC. Health care provider use of guideline-based smoking cessation interventions: results from the 2003 Wisconsin Tobacco Survey. Wisconsin Medical Journal. 2005;104(4):28–31.
    1. Grundey J, Thirugnanasambandam N, Kaminsky K, et al. Neuroplasticity in cigarette smokers is altered under withdrawal and partially restituted by nicotine exposition. Journal of Neuroscience. 2012;32(12):4156–4162.
    1. Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annual Review of Pharmacology and Toxicology. 2009;49:57–71.
    1. Ridderinkhof KR, Ullsperger M, Crone EA, Nieuwenhuis S. The role of the medial frontal cortex in cognitive control. Science. 2004;306(5695):443–447.
    1. Brega AG, Grigsby J, Kooken R, Hamman RF, Baxter J. The impact of executive cognitive functioning on rates of smoking cessation in the San Luis Valley Health and Aging Study. Age and Ageing. 2008;37(5):521–525.
    1. Rubinstein ML, Shiffman S, Moscicki A-B, Rait MA, Sen S, Benowitz NL. Nicotine metabolism and addiction among adolescent smokers. Addiction. 2013;108:406–412.
    1. Hall W, Madden P, Lynskey M. The genetics of tobacco use: methods, findings and policy implications. Tobacco Control. 2002;11(2):119–124.
    1. Furberg H, Kim Y, Dackor J, et al. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nature Genetics. 2010;42:441–447.
    1. Kreek MJ, Nielsen DA, Butelman ER, LaForge KS. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nature Neuroscience. 2005;8(11):1450–1457.
    1. Kendler KS, Neale MC, Sullivan P, Corey LA, Gardner CO, Prescott CA. A population-based twin study in women of smoking initiation and nicotine dependence. Psychological Medicine. 1999;29(2):299–308.
    1. Carmelli D, Swan GE, Robinette D, Fabsitz R. Genetic influence on smoking—a study of male twins. The New England Journal of Medicine. 1992;327(12):829–833.
    1. Niu T, Chen C, Ni J, et al. Nicotine dependence and its familial aggregation in Chinese. International Journal of Epidemiology. 2000;29:248–252.
    1. Osler M, Holst C, Prescott E, Sørensen TIA. Influence of genes and family environment on adult smoking behavior assessed in an adoption study. Genetic Epidemiology. 2001;21(3):193–200.
    1. Perrin AJ, Lee H. The undertheorized environment: Sociological theory and the ontology of behavioral genetics. Sociological Perspectives. 2007;50(2):303–322.
    1. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PloS One. 2012;7e37483
    1. Wärnberg J, Gomez-Martinez S, Romeo J, Díaz L-E, Marcos A. Nutrition, inflammation, and cognitive function. Annals of the New York Academy of Sciences. 2009;1153:164–175.
    1. Borson S, Scanlan J, Friedman S, et al. Modeling the impact of COPD on the brain. International Journal of Chronic Obstructive Pulmonary Disease. 2008;3:429–434.
    1. Borson S, Scanlan J, Friedman S, et al. Modeling the impact of COPD on the brain. International Journal of Chronic Obstructive Pulmonary Disease. 2008;3:429–434.
    1. Li J, Huang Y, Fei GH. The evaluation of cognitive impairment and relevant factors in patients with chronic obstructive pulmonary disease. Respiration. 2013;85(2):98–105.
    1. Dardiotis E, Giamouzis G, Mastrogiannis D, et al. Cognitive impairment in heart failure. Cardiology Research and Practice. 2012;2012:9 pages.595821
    1. Heaton RK, Grant I, McSweeny AJ. Psychologic effects of continuous and nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease. Archives of Internal Medicine. 1983;143(10):1941–1947.
    1. Parekh PI, Blumenthal JA, Babyak MA, et al. Gas exchange and exercise capacity affect neurocognitive performance in patients with lung disease. Psychosomatic Medicine. 2005;67:425–432.
    1. Grant I, Prigatano GP, Heaton RK, McSweeny AJ, Wright EC, Adams KM. Progressive neuropsychologic impairment and hypoxemia. Relationship in chronic obstructive pulmonary disease. Archives of General Psychiatry. 1987;44(11):999–1006.
    1. Haley AP, et al. Carotid artery intima-media thickness and cognition in cardiovascular disease. International Journal of Cardiology. 2007;121:148–154.
    1. Agustí A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don’t know (but should) Proceedings of the American Thoracic Society. 2007;4(7):522–525.
    1. Foglio K, Carone M, Pagani M, Bianchi L, Jones PW, Ambrosino N. Physiological and symptom determinants of exercise performance in patients with chronic airway obstruction. Respiratory Medicine. 2000;94(3):256–263.
    1. Spirduso W, et al. Exercise and Its Mediating Effects on Cognition. Champaign, Ill, USA: Human Kinetics; 2008.
    1. Emery CF, Hauck ER, Schein RL, MacIntyre NR. Psychological and cognitive outcomes of a randomized trial of exercise among patients with chronic obstructive pulmonary disease. Health Psychology. 1998;17(3):232–240.
    1. Ambrosino N, Bruletti G, Scala V, Porta R, Vitacca M. Cognitive and perceived health status in patient with chronic obstructive pulmonary disease surviving acute on chronic respiratory failure: a controlled study. Intensive Care Medicine. 2002;28(2):170–177.
    1. Kirkil G, Tug T, Ozel E, Bulut S, Tekatas A, Muz MH. The evaluation of cognitive functions with P300 test for chronic obstructive pulmonary disease patients in attack and stable period. Clinical Neurology and Neurosurgery. 2007;109(7):553–560.
    1. Damiani MF, Lacedonia D, Resta O. Influence of obstructive sleep apnea on cognitive impairment in patients with COPD. Chest. 2013;143:p. 1512.
    1. Potter GG, Steffens DC. Contribution of depression to cognitive impairment and dementia in older adults. Neurologist. 2007;13(3):105–117.
    1. Chang SS, Chen S, et al. Effect of coexisting chronic obstructive pulmonary disease and cognitive impairment on health outcomes in older adults. Journal of the American Geriatrics Society. 2012;60:1839–1846.
    1. Bourbeau J. Making pulmonary rehabilitation a success in COPD. Swiss Medical Weekly. 2010;140:p. w13067.
    1. Antonelli Incalzi R, Corsonello A, Pedone C, Corica F, Carbonin P, Bernabei R. Construct validity of activities of daily living scale: a clue to distinguish the disabling effects of COPD and congestive heart failure. Chest. 2005;127(3):830–838.
    1. Bourbeau J. Activities of life: the copd patient. Chronic Obstructive Pulmonary Disease. 2009;6(3):192–200.
    1. Schillerstrom JE, Horton MS, Royall DR. The impact of medical illness on executive function. Psychosomatics. 2005;46(6):508–516.
    1. Fix AJ, Daughton D, Kass I, Bell CW, Golden CJ. Cognitive functioning and survival among patients with chronic obstructive pulmonary disease. International Journal of Neuroscience. 1985;27(1-2):13–17.
    1. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. The New England Journal of Medicine. 2004;350(10):1005–1012.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren